Benzinga | Apr 14, 2021 07:10AM EDT

Rocket Pharmaceuticals Interim Data From Phase 1/2 Trial Of RP-L201 Showing Durable CD18 Expression, Improved Skin Lesions And Consistent Peripheral Vector Copy Numbers Up To 18-Months Post-Treatment

-- New Long-Term Follow-Up Data Demonstrate Durable CD18 Expression, Improved Skin Lesions, and Consistent Peripheral Vector Copy Numbers Up to 18-Months Post-Treatment --

-- Second Patient Nearing One-Year Primary Endpoint for Phase 2 Portion of Study --

-- Two Additional Patients with Shorter Follow-Up Demonstrate Evidence of Engraftment --

-- RP-L201 was Well Tolerated in All Patients --

-- More Comprehensive Phase 2 Results Expected in Second Half of 2021 --